Dean F Wong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2080755/publications.pdf

Version: 2024-02-01

81900 49909 8,248 145 39 87 citations g-index h-index papers 153 153 153 9454 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Associations Between Atrial Arrhythmias and Brain Amyloid Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2022, 86, 43-48.	2.6	O
2	The prospective association between periodontal disease and brain imaging outcomes: The Atherosclerosis Risk in Communities study. Journal of Clinical Periodontology, 2022, 49, 322-334.	4.9	5
3	Fragile X Mental Retardation Protein and Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome: A Pilot Study. Brain Sciences, 2022, 12, 314.	2.3	7
4	Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine. Human Brain Mapping, 2022, 43, 1419-1430.	3.6	11
5	Phase 1 Evaluation of C-CS1P1 to Assess Safety and Dosimetry in Human Participants Journal of Nuclear Medicine, 2022, , .	5.0	3
6	Carotid Intima-Media Thickness and Amyloid- \hat{l}^2 Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2022, , 1-6.	2.6	0
7	Brain Imaging Features Associated with 20-Year Cognitive Decline in a Community-Based Multiethnic Cohort without Dementia. Neuroepidemiology, 2022, 56, 183-191.	2.3	2
8	Neuronal insulin signaling and brain structure in nondemented older adults: the Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 2021, 97, 65-72.	3.1	11
9	An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. European Journal of Clinical Pharmacology, 2021, 77, 717-725.	1.9	10
10	Imaging-based indices of Neuropathology and gait speed decline in older adults: the atherosclerosis risk in communities study. Brain Imaging and Behavior, 2021, 15, 2387-2396.	2.1	12
11	Generalizability of findings from a clinical sample to a communityâ€based sample: A comparison of ADNI and ARIC. Alzheimer's and Dementia, 2021, 17, 1265-1276.	0.8	20
12	Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study. International Journal of Molecular Sciences, 2021, 22, 2863.	4.1	19
13	Brain imaging of cannabinoid type I (CB $<$ sub $>$ 1 $<$ /sub $>$) receptors in women with cannabis use disorder and male and female healthy controls. Addiction Biology, 2021, 26, e13061.	2.6	27
14	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Medicine, 2021, 18, e1003615.	8.4	38
15	Relative strengths of three linearizations of receptor availability: Saturation, Inhibition, and Occupancy plots. Journal of Nuclear Medicine, 2021, , jnumed.117.204453.	5.0	3
16	Deconvolution-based partial volume correction of PET images with parallel level set regularization. Physics in Medicine and Biology, 2021, 66, 145003.	3.0	6
17	Age of amyloid onset, but not amyloid accumulation rate, differs across APOEâ€e4 carriers vs. nonâ€carriers in three cohorts and three methods. Alzheimer's and Dementia, 2021, 17, .	0.8	0
18	The Relationship of Varenicline Agonism of $\hat{l}\pm4\hat{l}^22$ Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans. Nicotine and Tobacco Research, 2020, 22, 892-899.	2.6	8

#	Article	IF	CITATIONS
19	High Availability of the α7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸ F-ASEM PET. Journal of Nuclear Medicine, 2020, 61, 423-426.	5.0	22
20	Association of Intracranial Atherosclerotic Disease With Brain \hat{l}^2 -Amyloid Deposition. JAMA Neurology, 2020, 77, 350.	9.0	27
21	Ethnic disparities in pain processing among healthy adults: \hat{l} 4-opioid receptor binding potential as a putative mechanism. Pain, 2020, 161, 810-820.	4.2	11
22	Dataset of quantitative structured office measurements of movements in the extremities. Data in Brief, 2020, 31, 105876.	1.0	5
23	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome. Brain Sciences, 2020, 10, 899.	2.3	15
24	The association between midlife lipid levels and late-life brain amyloid deposition. Neurobiology of Aging, 2020, 92, 73-74.	3.1	9
25	Mid- and Late-Life Leisure-Time Physical Activity and Global Brain Amyloid Burden: The Atherosclerosis Risk in Communities (ARIC)-PET Study. Journal of Alzheimer's Disease, 2020, 76, 139-147.	2.6	4
26	Beta-amyloid (\hat{A}^2) uptake by PET imaging in older HIV+ and HIV- individuals. Journal of NeuroVirology, 2020, 26, 382-390.	2.1	15
27	Medial Temporal Tau Pathology Is Associated With Verbal Memory. Innovation in Aging, 2020, 4, 767-767.	0.1	0
28	A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neuroscience and Therapeutics, 2019, 25, 136-146.	3.9	5
29	Transcranial Recording of Electrophysiological Neural Activity in the Rodent Brain in vivo Using Functional Photoacoustic Imaging of Near-Infrared Voltage-Sensitive Dye. Frontiers in Neuroscience, 2019, 13, 579.	2.8	40
30	The effect of ApoE $\hat{l}\mu4$ on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. NeuroImage: Clinical, 2019, 22, 101795.	2.7	34
31	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	2.2	12
32	Association of PET-measured myocardial flow reserve with echocardiography-estimated pulmonary artery systolic pressure in patients with hypertrophic cardiomyopathy. PLoS ONE, 2019, 14, e0212573.	2.5	3
33	Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Neurotrauma, 2019, 36, 2549-2557.	3.4	10
34	Sex differences in the association between amyloid and longitudinal brain volume change in cognitively normal older adults. NeuroImage: Clinical, 2019, 22, 101769.	2.7	20
35	PET imaging of dopamine release in the frontal cortex of manganeseâ€exposed nonâ€human primates. Journal of Neurochemistry, 2019, 150, 188-201.	3.9	9
36	Cognitive Reserve in Midlife is not Associated with Amyloid- \hat{l}^2 Deposition in Late-Life. Journal of Alzheimer's Disease, 2019, 68, 517-521.	2.6	9

#	Article	IF	Citations
37	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology, 2019, 44, 598-605.	5.4	207
38	Synthesis and Evaluation of a New 18F-Labeled Radiotracer for Studying the GABAB Receptor in the Mouse Brain. ACS Chemical Neuroscience, 2018, 9, 1453-1461.	3.5	7
39	^{18} F-XTRA PET for Enhanced Imaging of the Extrathalamic $\hat{l}\pm4\hat{l}^22$ Nicotinic Acetylcholine Receptor. Journal of Nuclear Medicine, 2018, 59, 1603-1608.	5.0	15
40	Î ² -amyloid deposition is associated with gait variability in usual aging. Gait and Posture, 2018, 61, 346-352.	1.4	15
41	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor ImagingÂinÂObesity. JACC: Cardiovascular Imaging, 2018, 11, 320-332.	5.3	24
42	Metabotropic glutamate receptor 5 tracer [18F]-FPEB displays increased binding potential in postcentral gyrus and cerebellum of male individuals with autism: a pilot PET study. Cerebellum and Ataxias, 2018, 5, 3.	1.9	36
43	Characterization of 3 Novel Tau Radiopharmaceuticals, ¹¹ C-RO-963, ¹¹ C-RO-643, and ¹⁸ F-RO-948, in Healthy Controls and in Alzheimer Subjects. Journal of Nuclear Medicine, 2018, 59, 1869-1876.	5.0	81
44	Arterial stiffness and dementia pathology. Neurology, 2018, 90, e1248-e1256.	1.1	114
45	Preclinical Evaluation of ¹⁸ F-RO6958948, ¹¹ C-RO6931643, and ¹¹ C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 675-681.	5.0	71
46	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. Neurolmage, 2018, 165, 118-124.	4.2	27
47	P3â€423: INDEPENDENT AND SYNERGISTIC EFFECTS OF AMYLOID PATHOLOGY AND HIPPOCAMPAL NEURODEGENERATION ON COGNITIVE CHANGE IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1271.	0.8	0
48	The Association of Mid- and Late-Life Systemic Inflammation with Brain Amyloid Deposition: The ARIC-PET Study. Journal of Alzheimer's Disease, 2018, 66, 1041-1052.	2.6	20
49	Vestibular Function and Beta-Amyloid Deposition in the Baltimore Longitudinal Study of Aging. Frontiers in Aging Neuroscience, 2018, 10, 408.	3.4	6
50	Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 471-479.	2.4	40
51	Remission of Gilles de la Tourette Syndrome after Heat-Induced Dehydration. International Journal of Physical Medicine & Rehabilitation, 2018, 06, .	0.5	0
52	ICâ€Pâ€001: SURROGATES OF REGIONAL CEREBRAL BLOOD FLOW COMPUTED FROM DYNAMIC AMYLOID PET IMAGING. Alzheimer's and Dementia, 2018, 14, P14.	0.8	0
53	Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid deposition measured by PiB PET. Sleep, 2018, 41, .	1.1	53
54	Incorporating reflection boundary conditions in the Neumann series radiative transport equation: application to photon propagation and reconstruction in diffuse optical imaging. Biomedical Optics Express, 2018, 9, 1389.	2.9	3

#	Article	IF	CITATIONS
55	Image reconstruction in fluorescence molecular tomography with sparsity-initialized maximum-likelihood expectation maximization. Biomedical Optics Express, 2018, 9, 3106.	2.9	5
56	Metabolic Syndrome and Amyloid Accumulation in the Aging Brain. Journal of Alzheimer's Disease, 2018, 65, 629-639.	2.6	44
57	Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia, 2018, 14, 1565-1571.	0.8	98
58	Evaluation of ¹⁸ F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. Journal of Nuclear Medicine, 2018, 59, 1877-1884.	5.0	64
59	Voltage-sensitive dye delivery through the blood brain barrier using adenosine receptor agonist regadenoson. Biomedical Optics Express, 2018, 9, 3915.	2.9	17
60	Are dopamine receptor and transporter changes in Rett syndrome reflected in Mecp2-deficient mice?. Experimental Neurology, 2018, 307, 74-81.	4.1	15
61	Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain, 2018, 141, 2475-2485.	7.6	78
62	Family history of alcoholism is related to increased D ₂ /D ₃ receptor binding potential: a marker of resilience or risk?. Addiction Biology, 2017, 22, 218-228.	2.6	15
63	A three-step reconstruction method for fluorescence molecular tomography based on compressive sensing. , $2017,10059,$		5
64	Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition. JAMA - Journal of the American Medical Association, 2017, 317, 1443.	7.4	451
65	Listening to membrane potential: photoacoustic voltage-sensitive dye recording. Journal of Biomedical Optics, 2017, 22, 045006.	2.6	38
66	Molecular imaging of serotonin degeneration in mild cognitive impairment. Neurobiology of Disease, 2017, 105, 33-41.	4.4	61
67	Linking dopaminergic reward signals to the development of attentional bias: A positron emission tomographic study. Neurolmage, 2017, 157, 27-33.	4.2	46
68	Association between serotonin denervation and resting \hat{s} tate functional connectivity in mild cognitive impairment. Human Brain Mapping, 2017, 38, 3391-3401.	3.6	15
69	A radiative transfer equation-based image-reconstruction method incorporating boundary conditions for diffuse optical imaging. , 2017, 10137, .		2
70	Density of available striatal dopamine receptors predicts trait impulsiveness during performance of an attention-demanding task. Journal of Neurophysiology, 2017, 118, 64-68.	1.8	5
71	Development of a radioligand for imaging V $1\mathrm{a}$ vasopressin receptors with PET. European Journal of Medicinal Chemistry, 2017, 139, 644-656.	5. 5	8
72	Radioligand binding analysis of $\hat{l}\pm 2$ adrenoceptors with [11C]yohimbine in brain in vivo: Extended Inhibition Plot correction for plasma protein binding. Scientific Reports, 2017, 7, 15979.	3.3	14

#	Article	IF	CITATIONS
73	[ICâ€Pâ€188]: ON EVALUATION OF TAU ACCUMULATIONS IN LONGITUDINAL STUDIES OF ALZHEIMER'S DISEASE (AD): IMPLICATIONS FROM A PET STUDY WITH [18F]RO6958948. Alzheimer's and Dementia, 2017, 13, P139.	0.8	5
74	Notice of Removal: Real-time recording of neuronal voltage membrane variation during seizure using transcranial photoacoustic voltage-sensitive dye imaging. , 2017, , .		0
75	Learning Mechanisms Underlying Value-Driven Attention. Journal of Vision, 2017, 17, 1101.	0.3	O
76	ICâ€Pâ€022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale. Alzheimer's and Dementia, 2016, 12, P25.	0.8	6
77	IC-P-125: Arterial Stiffness and \hat{I}^2 -Amyloid Deposition in The ARIC-PET Study. , 2016, 12, P93-P93.		O
78	P3-242: Conversion of Amyloid Quantitation with Florbetapir SUVR to the Centiloid Scale., 2016, 12, P919-P920.		0
79	A multivariate nonlinear mixed effects model for longitudinal image analysis: Application to amyloid imaging. Neurolmage, 2016, 134, 658-670.	4.2	68
80	Individual estimates of age at detectable amyloid onset for risk factor assessment. Alzheimer's and Dementia, 2016, 12, 373-379.	0.8	63
81	The ARIC-PET amyloid imaging study. Neurology, 2016, 87, 473-480.	1.1	119
82	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. Journal of Medicinal Chemistry, 2016, 59, 7840-7855.	6.4	47
83	The Role of Dopamine in Value-Based Attentional Orienting. Current Biology, 2016, 26, 550-555.	3.9	96
84	CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease—A Preliminary Report. PLoS ONE, 2016, 11, e0164762.	2.5	16
85	P4-187: Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology, and presymptomatic cerebral amyloid accumulation., 2015, 11, P851-P852.		1
86	P4â€185: First inâ€human PET study of 3 novel tau radiopharmaceuticals: [¹¹ C]RO6924963, [¹¹ C]RO6931643, and [¹⁸ F]RO6958948. Alzheimer's and Dementia, 2015, 11, P850.	0.8	12
87	Changes in $\hat{Al^2}$ biomarkers and associations with APOE genotype in $2\hat{Al}$ longitudinal cohorts. Neurobiology of Aging, 2015, 36, 2333-2339.	3.1	60
88	P4-186: Kinetic evaluation of three newly developed radioligands for human tau imaging. , 2015, 11, P851-P851.		0
89	GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. Journal of the Neurological Sciences, 2015, 356, 118-123.	0.6	42
90	Voxelwise Relationships Between Distribution Volume Ratio and Cerebral Blood Flow: Implications for Analysis of \hat{l}^2 -Amyloid Images. Journal of Nuclear Medicine, 2015, 56, 1042-1047.	5.0	11

#	Article	IF	CITATIONS
91	Quantification of [$\langle \sup \rangle 11 \langle \sup \rangle C$]yohimbine Binding to Î $\pm \langle \sup \rangle 2 \langle \sup \rangle$ Adrenoceptors in Rat Brain $\langle i \rangle$ in vivo $\langle i \rangle$. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 501-511.	4.3	13
92	Risky decision-making and ventral striatal dopamine responses to amphetamine: A positron emission tomography [11C]raclopride study in healthy adults. NeuroImage, 2015, 113, 26-36.	4.2	29
93	Performance assessment of a NaI(Tl) gamma counter for PET applications with methods for improved quantitative accuracy and greater standardization. EJNMMI Physics, $2015, 2, .$	2.7	18
94	Deformation field correction for spatial normalization of PET images. NeuroImage, 2015, 119, 152-163.	4.2	4
95	Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers. PLoS ONE, 2014, 9, e113694.	2.5	36
96	Doseâ€dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [¹¹ C]ABP688 PET imaging. Synapse, 2014, 68, 565-573.	1.2	21
97	Human Brain Imaging of $\hat{l}\pm7$ nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy. Molecular Imaging and Biology, 2014, 16, 730-738.	2.6	69
98	Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophrenia Research, 2014, 159, 124-129.	2.0	52
99	Objectively measured sleep and \hat{l}^2 -amyloid burden in older adults: A pilot study. SAGE Open Medicine, 2014, 2, 205031211454652.	1.8	41
100	An In Vivo Evaluation of Cerebral Cortical Amyloid with [18F]Flutemetamol Using Positron Emission Tomography Compared with Parietal Biopsy Samples in Living Normal Pressure Hydrocephalus Patients. Molecular Imaging and Biology, 2013, 15, 230-237.	2.6	36
101	Self-reported Sleep and \hat{l}^2 -Amyloid Deposition in Community-Dwelling Older Adults. JAMA Neurology, 2013, 70, 1537-43.	9.0	414
102	Characterization of $[11C]RO5013853$, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. NeuroImage, 2013, 75, 282-290.	4.2	26
103	Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography. NeuroImage, 2013, 75, 291-300.	4.2	16
104	¹⁸ F-FPEB, a PET Radiopharmaceutical for Quantifying Metabotropic Glutamate 5 Receptors: A First-in-Human Study of Radiochemical Safety, Biokinetics, and Radiation Dosimetry. Journal of Nuclear Medicine, 2013, 54, 388-396.	5.0	95
105	PET Imaging of High-Affinity $\hat{l}\pm4\hat{l}^22$ Nicotinic Acetylcholine Receptors in Humans with ¹⁸ F-AZAN, a Radioligand with Optimal Brain Kinetics. Journal of Nuclear Medicine, 2013, 54, 1308-1314.	5.0	46
106	Generalized dynamic PET inter-frame and intra-frame motion correction - Phantom and human validation studies. , 2012, , .		7
107	Generalized inter-frame and intra-frame motion correction in PET imaging - a simulation study. , $2011,$, .		5
108	Motion-incorporated partial volume correction: Methodology and validation. , 2010, , .		0

#	Article	IF	CITATIONS
109	In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand ¹⁸ F-AV-45 (Flobetapir F 18). Journal of Nuclear Medicine, 2010, 51, 913-920.	5.0	607
110	Direct 4D parametric image reconstruction with plasma input and reference tissue models in reversible binding imaging. , 2009 , , .		6
111	The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. Neuropsychopharmacology, 2009, 34, 187-203.	5.4	161
112	Single photon emission computed tomography experience with (⟨i⟩S⟨ i⟩)â€5â€[⟨sup⟩123⟨ sup⟩1]iodoâ€3â€(2â€azetidinylmethoxy)pyridine in the living human brain of smoke and nonsmokers. Synapse, 2009, 63, 339-358.	er s 1.2	24
113	Mechanisms of Dopaminergic and Serotonergic Neurotransmission in Tourette Syndrome: Clues from an In Vivo Neurochemistry Study with PET. Neuropsychopharmacology, 2008, 33, 1239-1251.	5.4	227
114	Is getting older all that rewarding?. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14751-14752.	7.1	3
115	Direct 4D reconstruction of parametric images incorporating anato-functional joint entropy. , 2008, ,		5
116	Imaging in drug discovery, preclinical, and early clinical development. Journal of Nuclear Medicine, 2008, 49, 26N-28N.	5.0	6
117	Brain imaging research: Does the science serve clinical practice?. International Review of Psychiatry, 2007, 19, 541-558.	2.8	33
118	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1533-1539.	4.3	1,840
119	Data Processing Methods for a High Throughput Brain Imaging PET Research Center. , 2006, , .		0
120	Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving. Neuropsychopharmacology, 2006, 31, 2716-2727.	5.4	280
121	Characterization of dose dependent norepinephrine transporter blockade by atomoxetine in human brain using 11C MeNER PET. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S599-S599.	4.3	2
122	Spectral analysis with a minimal basis functions approach for quantification of ligand-receptor dynamic PET study. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S634-S634.	4.3	2
123	Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Molecular Imaging and Biology, 2003, 5, 350-362.	2.6	54
124	Mechanism of New Antipsychotic Medications. Archives of General Psychiatry, 2003, 60, 974.	12.3	200
125	Positron emission tomography—a tool for identifying the effects of alcohol dependence on the brain. Alcohol Research, 2003, 27, 161-73.	1.0	14
126	¹¹ C-MCG: Synthesis, Uptake Selectivity, and Primate PET of a Probe for Glutamate Carboxypeptidase II (NAALADase). Molecular Imaging, 2002, 1, 153535002002021.	1.4	27

#	Article	IF	CITATIONS
127	In Vivo Imaging of D2 Dopamine Receptors in Schizophrenia. Archives of General Psychiatry, 2002, 59, 31.	12.3	19
128	Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride. Neuropsychopharmacology, 2002, 27, 248-259.	5.4	261
129	Specific Binding of [11C]Raclopride and N-[3H]Propyl-Norapomorphine to Dopamine Receptors in Living Mouse Striatum: Occupancy by Endogenous Dopamine and Guanosine Triphosphate–Free G Protein. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 596-604.	4.3	68
130	The Competition Between Endogenous Dopamine and Radioligands for Specific Binding to Dopamine Receptors. Annals of the New York Academy of Sciences, 2002, 965, 440-450.	3.8	28
131	Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans., 1999, 32, 44-50.		50
132	GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans. Synapse, 1999, 33, 268-273.	1.2	50
133	Cerebral Glucose Utilization Is Reduced in Second Test Session. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 704-712.	4.3	43
134	Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse, 1995, 20, 37-43.	1.2	161
135	Cerebral Glucose Utilization in Polysubstance Abuse. Neuropsychopharmacology, 1995, 13, 21-31.	5.4	48
136	Model for reduced brain dopamine in Lesch-Nyhan syndrome and the mentally retarded: Neurobiology of neonatal-6-hydroxydopamine-lesioned rats. Mental Retardation and Developmental Disabilities Research Reviews, 1995, 1, 111-119.	3.6	23
137	Cerebral Glucose Utilization in Polysubstance Abuse. Neuropsychopharmacology, 1995, 13, 21-31.	5.4	10
138	Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 1993, 15, 263-275.	1.2	17
139	In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse, 1992, 10, 169-172.	1.2	85
140	In vivo studies of [1251]iodobenzamide and [11C]iodobenzamide: A ligand suitable for positron emission tomography and single photon emission tomography imaging of cerebral D2 dopamine receptors. Synapse, 1992, 12, 236-241.	1.2	6
141	Effects of Vasopressin on Blood-Brain Transfer of Methionine in Dogs. Journal of Neurochemistry, 1992, 59, 1421-1429.	3.9	11
142	Effects of Substance Abuse on Ventricular and Sulcal Measures Assessed by Computerised Tomography. British Journal of Psychiatry, 1991, 159, 217-221.	2.8	26
143	Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse, 1991, 9, 188-194.	1.2	126
144	Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using N1-([11C]-methyl)-2-BR-LSD. Synapse, 1987, 1, 393-398.	1.2	94

#	Article	IF	CITATIONS
145	Positron emission tomographic study of D2 dopamine receptor binding and CSF biogenic amine metabolites in rett syndrome. American Journal of Medical Genetics Part A, 1986, 25, 201-210.	2.4	22